Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 37Paclitaxel 18Cisplatin 18Carboplatin 14Nivolumab 13Hyperthermic Intraperitoneal Chemotherapy 13Docetaxel 11Cyclophosphamide 11Oxaliplatin 9Irinotecan 9Fluorouracil 9atezolizumab 8Trastuzumab 8Leucovorin 8Bevacizumab 8fludarabine 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Ipilimumab 6Gemcitabine 6Mitomycin 5Cytoreduction Surgical Procedures 5Capecitabine 5durvalumab 4cemiplimab 4aldesleukin 4Taxes 4Psychiatric Rehabilitation 4Platinum 4Drug Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Ferrosoferric Oxide × Gynecologic × Clear all
NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡